A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

NCT05296733 | Completed Phase 1 FDA Drug

• 2 other identifiers: 1404-00102021-006247-10
• Study Type: interventional
• Target: 82
• Locations: 6 countries
• Sites: 13

Brief Summary

This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is taken up in the body. The purpose of Part 2 is to find out whether having liver problems influences how people with overweight and obesity tolerate different doses of BI 456906. In Part 1, participants get a single injection of BI 456906 under their skin and stay at the study site for 2 nights afterwards. They are in the study for about a month. During this time, they visit the study site about 8 more times. The doctors compare the amount of BI 456906 in the blood of healthy people and people with liver problems. In Part 2, participants get 1 or 2 injections of BI 456906 once a week under their skin for 28 weeks. At the beginning, they get lower doses of BI 456906. Over time, they get higher doses until they reach a certain dose of BI 456906. This dose is then maintained until the end of the treatment. Participants in Part 2 are in the study for about 7 months. During this time, they visit the study site about 16 times and get about 15 phone calls from the site staff. The doctors record the number of people with health problems that could have been caused by treatment with BI 456906. They compare the results between participants with liver problems and those without liver problems. In both parts, doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

Healthy; Liver Diseases; Obesity

Outcome Measures

Primary Outcomes (3)

• Part A: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

  Up to 360 hours

• Part A: Maximum measured concentration of BI 456906 in plasma (Cmax)

  Up to 360 hours

• Part B: Percentage of patients treated who experience treatment-emergent adverse event

  Up to Day 218

Secondary Outcomes (1)

• Part A: Percentage of patients treated who experience treatment-emergent adverse event

  Up to Day 35

Study Arms (7)

Part A: BI 456906: Cohort 1

EXPERIMENTAL

Healthy subjects

Drug: BI 456906

Part A: BI 456906: Cohort 2

EXPERIMENTAL

Patients with cirrhosis + Child-Turcotte-Pugh (CTP) Class A

Drug: BI 456906

Part A: BI 456906: Cohort 3

EXPERIMENTAL

Patients with cirrhosis + CTP Class B

Drug: BI 456906

Part A: BI 456906: Cohort 4

EXPERIMENTAL

Patients with cirrhosis + CTP Class C

Drug: BI 456906

Part B: BI456906: Cohort 1

EXPERIMENTAL

Patients with overweight/obesity without cirrhosis/hepatic impairment

Drug: BI 456906

Part B: BI456906: Cohort 2

EXPERIMENTAL

Patients with overweight/obesity with cirrhosis + CTP Class A

Drug: BI 456906

Part B: BI456906: Cohort 3

EXPERIMENTAL

Patients with overweight/obesity with cirrhosis + CTP Class B

Drug: BI 456906

Interventions

BI 456906 DRUG

BI 456906

Also known as: survodutide

Part A: BI 456906: Cohort 1; Part A: BI 456906: Cohort 2; Part A: BI 456906: Cohort 3; Part A: BI 456906: Cohort 4; Part B: BI456906: Cohort 1; Part B: BI456906: Cohort 2; Part B: BI456906: Cohort 3

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects with age ≥18 years (or the minimum country specific age of consent if \>18 years) and 75 years, inclusive at the screening visit.
• Body mass index (BMI) of 18.5-40.0 kg/m2 (inclusive).
• Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
• Women of childbearing potential must be willing and able to use two forms of effective contraception where at least one form is highly effective method of birth control per ICH M3 (R2) that results in a low failure rate (i.e. \<1% per year when used consistently and correctly). A list of contraception methods meeting these criteria is provided in the subject information. Please note that oral contraceptives are not allowed during the treatment period.
• A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
• Part B:
• Male or female subjects between the ages of ≥18 (or the minimum country specific age of consent if \>18 years) and 75 years, inclusive, at the screening visit.
• Subjects with overweight or obesity, defined as BMI ≥27 kg/m2 at the screening visit.
• A minimum absolute body weight of 70 kg for females and 80 kg for males at the screening visit.
• Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.

You may not qualify if:

• Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula).
• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, manifest hypo- or hyperthyroidism at screening.
• Calcitonin ≥20 pg/mL (5.84 pmol/L) at the screening visit.
• History of chronic or acute pancreatitis or elevation of serum lipase/amylase \>2×ULN, or fasting serum triglyceride levels of \>500 mg/dL (\>5.65 mmol/L) at screening.
• Part B:
• Prior surgery of the gastrointestinal tract that could interfere with body weight (including minimally invasive/endoscopic bariatric devices, bariatric surgery including metabolic operation that involves resection and/or reconstruction of any portion of the gastrointestinal tract) except appendectomy and simple hernia repair before randomization. However, a subject previously treated with reversible weight loss devices such as gastric banding, or intragastric balloon and removed longer than 12 months before screening should not be excluded.
• Glycosylated Hemoglobin, Type A1 (HbA1c) ≥11% at screening or diagnosed with type 1 diabetes mellitus.
• Exposure to Glucagon-like-peptide 1 (GLP-1) receptor agonist-based therapies (within 3 months prior to screening or within 5 half-lives of the drug, whichever is longer).
• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, manifest hypo- or hyperthyroidism at screening.

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (13)

Arizona Liver Health

Chandler, Arizona, 85224, United States

Location

Covenant Metabolic Specialists, LLC

Fort Myers, Florida, 33912, United States

Location

Covenant Metabolic Specialists, LLC

Sarasota, Florida, 34240, United States

Location

American Research Corporation at the Texas Liver Institute

San Antonio, Texas, 78215, United States

Location

IMA Clinical Research San Antonio

San Antonio, Texas, 78229, United States

Location

Universitätsklinikum Bonn AöR

Bonn, 53127, Germany

Location

Universitätsklinikum Hamburg-Eppendorf

Hamburg, 20246, Germany

Location

Universitätsklinikum Ulm

Ulm, 89081, Germany

Location

Semmelweis University

Budapest, 1083, Hungary

Location

CRU Hungary Ltd.

Kistarcsa, 2140, Hungary

Location

New Zealand Clinical Research (NZCR)

Auckland, 1010, New Zealand

Location

Dr. Piotr Napora, Center of Clinical Research

Wroclaw, 51162, Poland

Location

SUMMIT CLINICAL RESEARCH, s.r.o.

Bratislava, 83101, Slovakia

Location

Related Publications (1)

• Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takacs I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R; NCT05296733 Investigators. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024 Nov;81(5):837-846. doi: 10.1016/j.jhep.2024.06.003. Epub 2024 Jun 8.

  PMID: 38857788 DERIVED

Related Links

• Related Info

MeSH Terms

Conditions

Liver Diseases; Obesity

Interventions

BI 456906

Condition Hierarchy (Ancestors)

Digestive System Diseases; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2022
• First Posted: March 25, 2022
• Study Start: April 27, 2022
• Primary Completion: December 29, 2023
• Study Completion: December 29, 2023
• Last Updated: August 15, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

HU (2); US (5); NZ (1); SL (1); DE (3); PL (1)